Accéder au contenu
Merck

Principaux documents

Voir toute la documentation

567430

Sodium Butyrate

≥98% (titration), apoptosis inducer, solid

Synonyme(s) :

Sodium Butyrate, Butyric Acid, Na, NaB, HDAC Inhibitor V

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :
C4H7NaO2
Numéro CAS:
156-54-7
Poids moléculaire :
110.09
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD00002816
Assay:
≥98% (titration)
Form:
solid
Quality level:
200
Storage condition:
OK to freeze, desiccated (hygroscopic)
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Sodium Butyrate, A short chain fatty acid that has been shown to induce apoptosis in colon carcinoma cell lines by a p53-independent pathway.

Quality Level

200

description

RTECS - ET6400000

assay

≥98% (titration)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, desiccated (hygroscopic)

color

white

solubility

water: 2 mg/mL

shipped in

ambient

storage temp.

−20°C

SMILES string

[Na+].[O-]C(=O)CCC

InChI

1S/C4H8O2.Na/c1-2-3-4(5)6;/h2-3H2,1H3,(H,5,6);/q;+1/p-1

InChI key

MFBOGIVSZKQAPD-UHFFFAOYSA-M

General description

A short chain fatty acid that has been shown to induce apoptosis in colon carcinoma cell lines by a p53-independent pathway. Inhibits c-myc splicing and interferes with signal transduction processes, including the release of Ca2+ from intracellular stores. Reduces histamine-induced calcium mobilization in C6 glioma cells. Down-regulates the activity of the serine/threonine protein kinase casein kinase II in HT29 cells.

Biochem/physiol Actions

Cell permeable: no
Primary Target
Induce apoptosis
Product does not compete with ATP.
Reversible: no

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Ou, H.C., et al. 1997. Neuroreport 8, 1375.
Russo, G.L., et al. 1997. Biochem. Biophys. Res. Commun. 233, 673.
Krupitza, G., et al. 1995. Carcinogenesis16, 1199.
Calabresse, C., et al. 1993. Biochem. Biophys. Res. Commun.195, 31.
Hague, A., et al. 1993. Int. J. Cancer55, 498.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Irritant (B)

Still not finding the right product?

Explore all of our products under

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2

Classe de stockage

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

C Pellegrini et al.
NPJ Parkinson's disease, 8(1), 9-9 (2022-01-14)
Bowel inflammation, impaired intestinal epithelial barrier (IEB), and gut dysbiosis could represent early events in Parkinson's disease (PD). This study examined, in a descriptive manner, the correlation among enteric α-synuclein, bowel inflammation, impairments of IEB and alterations of enteric bacteria